Navigation Links
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Date:1/4/2012

FREMONT, Calif., Jan. 4, 2012 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION).  QPI-1007 exhibited no dose limiting toxicities up to and including the highest dose of 6 milligrams enabled in this study, which is the highest dose of synthetic siRNA tested in the clinic following intravitreal administration.  After 3 months of follow up, patients treated in the study by a single dose of QPI-1007 exhibited no further loss of visual acuity, whereas vision loss was observed in previous studies(1) in non-treated NAION patients with similar initial disease severity. With the exception of one patient whose vision remained stable, all patients exhibited letter gains compared to baseline at screening, with some patients gaining 3-lines or more by 3 months after treatment.

The ongoing Phase 1 open-label, dose-escalation study, which is being conducted in 22 sites in the USA and 6 sites in Israel, has enrolled a total of 38 patients in two strata: Stratum I was a dose-escalation safety study in patients who are legally blind secondary to chronic optic nerve atrophy or retinal degeneration and is fully enrolled; Stratum II was designed to further evaluate safety and to assess for potential biological activity of QPI-1007 in recent-onset NAION patients by monitoring changes in visual function  following drug administration.

In Stratum II, two cohorts of ten patients each were given a single intravitreal injection of one of two doses of QPI-1007. After one month of follow-up, 40% of patients in Cohort 1 and 60% of patients in Cohort 2 gained 3 or more lines of visual acuity. At
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... 7, 2007 - REGENERX,BIOPHARMACEUTICALS' (AMEX: RGN), www.regenerx.com ... the 2007 Association for Research in,Vision and ... May 9th to discuss TB4's ability to ... process closely,associated with inflammation that, if not ...
... TSX-V: PGA, VANCOUVER, May 07, 2007 /PRNewswire-FirstCall/ - ... results from its Phase I/II study of PAC-113, ... and active,in the treatment of oral Candida infection ... of care. Based on these results,the Company plans ...
Cached Medicine Technology:Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting 2Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting 3Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 2Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 3Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 4Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 5
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... 17 Clarent Hospital Corporation ... 12, 2007, the Company,s Board ... cash distribution to stockholders of ... is payable on October 31, ...
... 17 The Channel Islands,Alzheimer,s Institute recently received ... be received in four payments of $30,000,each beginning ... Institute is located on the campus of,California State ... donation are at least two student research,scholarships for ...
... Explanations and Insightful Tips for Finding ... Affordable Health Insurance for Your Family, SAN ... a leading source for online,health insurance quotes and ... library of consumer resources: the,Family Health Insurance Guide. Inspired ...
... Prudence Hall,founder of The Hall Center in Santa Monica, ... health of her patients. It wasn,t until she became,immersed ... started investigating her birth control patients more carefully.,"I was ... old patients on the,pill, had hormone levels that were ...
... establishing the Dyslexia Research Laboratory at Beth Israel Deaconess ... dramatic transformation in thinking among both scientists and the ... a host of explanations offered to explain dyslexia, says ... BIDMC whose work has played a key role in ...
... food is needed, study suggests , , WEDNESDAY, Oct. 17 ... to blame, research suggests. , Scientists from the University ... dopamine, a brain chemical that helps make eating and ... more food. , "We weren,t studying obesity, per se, ...
Cached Medicine News:Health News:Channel Islands Alzheimer's Institute Receives $120,000 Donation 2Health News:Health Insurance Finders Debuts A Comprehensive Guide to Family Health Insurance 2Health News:Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients 2Health News:Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients 3Health News:BIDMC Dyslexia Research Lab celebrates 25th anniversary 2Health News:Genes Might Help Drive Overeating 2Health News:Genes Might Help Drive Overeating 3
... is a safe, non-surgical process that ... tighten skin and reverse the signs ... dermis to cause collagen contraction while ... In addition, Titan can stimulate long-term ...
... The smallest, lightest, smartest choice , ... or neurological, ... environment. But will the device ... on its signal quality? Will the battery last? Is it comfortable, ...
... The modular AU5400 is a high-volume analyzer ... productivity of the AU5200 analyzer and the ... automates and consolidates chemistry-immuno testing with up ... to 6,600 tests per hour. Choose from ...
... the quantitative determination of Erythropoietin (EPO) in human ... diagnostic use, as an aid in the diagnosis ... the administration of recombinant erythropoietin as a biologic ... erythropoietin assay may be used also to aid ...
Medicine Products: